If You Invested $1,000 in Mimedx Group Inc (MDXG)
This article analyzes the historical performance of a $1,000 investment in Mimedx Group Inc (MDXG) over 1, 5, and 10 years, showing significant losses and underperformance compared to the S&P 500. It also provides a detailed company profile, including its focus on regenerative medicine and advanced wound care, product portfolio, clinical evidence, market applications, operations, regulatory context, corporate governance, and current financial metrics.
MiMedx Group, Inc.(NasdaqCM: MDXG) added to Russell 2000 Value Benchmark
MiMedx Group, Inc. (NasdaqCM: MDXG) has been added to the Russell 2000 Value Benchmark, according to a report published on June 29, 2026. This news comes alongside several other index adjustments for the company on the same day and preceding days, indicating a re-evaluation of its classification within various Russell benchmarks. The article also provides a company profile, financial ratings, and analyst consensus for MiMedx Group.
MiMedx Group, Inc.(NasdaqCM: MDXG) dropped from Russell 2000 Growth Benchmark
MiMedx Group, Inc. (NasdaqCM: MDXG), a placental biologics company, has been removed from the Russell 2000 Growth Benchmark. This news comes amidst recent product launches like G4Derm Plus and Choriofix, and a strategic move to eliminate the COO role for cost savings. The company's stock has seen a 42.69% decrease year-to-date, despite analysts' consensus to "BUY" with an average target price significantly higher than its current close.
MDXG - Mimedx Group Inc Latest SEC Filings
This article provides a detailed financial overview of Mimedx Group Inc (MDXG), including its latest stock performance, key financial metrics, market capitalization, and various valuation ratios. It also lists insider and institutional ownership, profitability, and sales growth figures, giving a comprehensive snapshot of the company's current financial health and market position.
MiMedx Group, Inc.(NasdaqCM: MDXG) added to Russell 2000 Value-Defensive Index
MiMedx Group, Inc. (NasdaqCM: MDXG) has been added to the Russell 2000 Value-Defensive Index. This announcement follows recent news where the company was dropped from both the Russell 2000 Growth Benchmark and the Russell 3000E Growth Benchmark. The company specializes in placental biologics for wound care, burn, and surgical sectors.
Enterprise value to EBIT forward of MiMedx Group, Inc – NASDAQ:MDXG
This article provides financial information for MiMedx Group, Inc (NASDAQ: MDXG), specifically focusing on its Enterprise Value to EBIT (Earnings Before Interest and Taxes) forward metric. It details where to find this data within the TradingView platform's market information for the company.
Enterprise value to EBIT forward of MiMedx Group, Inc – BOATS:MDXG
The article focuses on the enterprise value to EBIT forward metric for MiMedx Group, Inc (MDXG) within the Blue Ocean Alternative Trade System (BOATS). It appears to be a financial data page from TradingView, displaying the metric's value, change, and percentage change. The content primarily shows navigation elements and data source attributions rather than a descriptive analysis.
Price to earnings forward of MiMedx Group, Inc – NASDAQ:MDXG
This article provides the "Price to earnings forward" metric for MiMedx Group, Inc (NASDAQ: MDXG) on TradingView. It indicates that the market was closed at the time of viewing, with no trades having occurred. The content mainly consists of navigation links and footers typical of a financial data platform.
MiMedx Group, Inc. Actuals & Estimates (BOATS:MDXG)
This article provides an overview of MiMedx Group, Inc. (MDXG) financials and analyst estimates. It covers historical financial data, future price forecasts from analysts, key dates like the next earnings report, and detailed financial figures including recent earnings, revenue, net income, and EBITDA. The article also addresses common questions about the company's stock, such as its ticker, historical price performance, dividend policy, and employee count.
Price to book forward of MiMedx Group, Inc – BOATS:MDXG
This article provides the "Price to book forward" financial metric for MiMedx Group, Inc (MDXG). It is presented as part of TradingView's financial data for the company. The page indicates that no trades were made when the market was closed.
Price to sales forward of MiMedx Group, Inc – NASDAQ:MDXG
This article provides financial data, specifically the "Price to sales forward" for MiMedx Group, Inc (NASDAQ: MDXG). The content appears to be a truncated financial data display page from TradingView, offering an overview, financials, news, and other market-related information for the company. The specific value and change of the "Price to sales forward" are indicated as present but not displayed in the provided text.
MiMedx Group, Inc. Actuals & Estimates (NASDAQ:MDXG)
This article provides an overview of MiMedx Group, Inc. (NASDAQ: MDXG) financials, stock performance, and analyst estimates. It includes current stock price, historical highs and lows, market capitalization, volatility, earnings reports, revenue, net income, and future forecasts, along with answers to frequently asked questions about investing in MDXG.
MIMEDX (MDXG) CCO sees 19,820 shares withheld to cover tax on RSU vesting
MIMEDX GROUP, INC.'s Chief Commercial Officer, Kimberly Maersk-Moller, had 19,820 shares withheld by the company at $3.83 per share to cover tax obligations upon the vesting of restricted stock. This was a tax-withholding disposition, not an open-market sale, and she retains a substantial equity position of 309,630 shares after the transaction. The filing emphasizes that this is a routine administrative tax matter and does not reflect a discretionary trade.
MDXG Forecast — Price Target — Prediction for 2027
This article provides a forecast for MiMedx Group, Inc (MDXG) stock, including analyst price targets, past performance, and financial data. Five analysts predict a max estimate of $8.00 and a min estimate of $5.00, while the stock currently trades at $3.81. Key financial metrics, upcoming earnings dates, and historical stock performance are also detailed.
MiMedx Group (MDXG) Stock Faces Mixed Analyst Target Changes After Guidance Cut
Analysts have issued mixed reactions to MiMedx Group's recent guidance cut, with some trimming price targets by US$1 to US$5, while the modeled fair value remains at US$6.50. This reflects a balance between optimism for the business and concerns over execution and current stock valuation. The narrative highlights key factors like demographics, new product launches, and risks from Medicare reimbursement changes.
MiMedx Group Inc (MDXG) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of MiMedx Group Inc (MDXG), noting its current price momentum score of 6.60 and its ranking in the Biotechnology & Medical Research industry. It details the stock's support and resistance levels, and analyzes various technical indicators and moving averages to offer a technical summary and trading signals. The analysis suggests the stock is currently suitable for range-bound swing trading, with a majority of indicators showing buy signals.
MiMedx Group Inc (MDXG) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of MiMedx Group Inc (MDXG), noting its current valuation score of 6.65, which ranks 314 out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio is 17.37, significantly below its recent high but substantially above its recent low. The article indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
MiMedx Group Inc (MDXG) Institutional Confidence
This article analyzes the institutional confidence in MiMedx Group Inc. (MDXG), noting its institutional shareholding score of 7.00, which ranks 81st in the Biotechnology & Medical Research industry. Institutional shareholding proportion increased by 8.73% quarter-over-quarter to 78.40%, with James Simons being the largest institutional shareholder. The article lists major institutional holders and their changes in shareholding.
MiMedx Group Inc (MDXG) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for MiMedx Group Inc (MDXG), noting its current earnings forecast score is 8.00, ranking 163 out of 388 in its industry. Analysts have an average price target of $12.00, with most recommending a "Buy" trend. The expected revenue for the next quarter is $63.46M, and the EPS is projected at -$0.04.
MiMedx Group Inc (MDXG) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of MiMedx Group Inc (MDXG), listing its major shareholders and institutional holdings as of recent reporting periods. It identifies top individual shareholders like EW Healthcare Partners and BlackRock, categorizes shareholders by type (e.g., Investment Advisor, Venture Capital), and provides a historical overview of institutional shareholding trends, including the number of institutions, shares held, and proportional changes over time. The article also lists various ETFs that hold MDXG shares.
MiMedx Shareholders Back Board, Pay and Bylaw Changes
MiMedx Group shareholders have approved amendments to the company's bylaws, including raising the cap on public-company boards its CEO can serve on to three. Additionally, investors re-elected seven directors, endorsed executive compensation, and ratified Deloitte & Touche LLP as the independent auditor for the 2026 fiscal year. While MiMedx (MDXG) shows strong financial performance and low leverage, its recent growth is weakening, and technical indicators are neutral to weak, leading Spark’s AI Analyst to rate the stock as "Neutral."
MiMedx (NASDAQ: MDXG) director Tiffany Olson receives 50,913-share stock grant
MiMedx director Tiffany Olson was granted 50,913 shares of common stock at $3.64 per share as a restricted stock grant for non-employee directors. This equity award vests upon the earlier of 12 months or the next meeting of shareholders and is exempt under Rule 16b-3. Following this grant, Ms. Olson directly holds 108,510 shares of common stock, with the transaction coded as a compensation-related equity grant rather than an open-market purchase.
Director Dorothy Puhy granted 50,913 MDXG shares in annual stock award
MiMedx Group director Dorothy E. Puhy received an annual restricted stock award of 50,913 shares of common stock, valued at $3.64 per share. This transaction, exempt under Rule 16b-3, increases her direct holdings to 108,510 shares. The award is part of her compensation as a non-employee director and will vest upon the earlier of 12 months or the next shareholder meeting.
MIMEDX (NASDAQ: MDXG) awards 50,913 restricted shares to director Todd Newton
MIMEDX (NASDAQ: MDXG) director Todd Newton was awarded 50,913 restricted shares of common stock as part of his annual compensation. The shares were granted at a reference price of $3.64 each and are exempt under Rule 16b-3. The award will vest after 12 months or at the next shareholder meeting, bringing Newton's total direct holdings to 463,684 shares.
MIMEDX (MDXG) director William Hawkins receives 50,913-share restricted stock grant
MIMEDX Group, Inc. director William A. Hawkins was granted 50,913 shares of restricted common stock at $3.64 per share as compensation for his non-employee director service. This grant is exempt under Rule 16b-3 and vests upon the earlier of 12 months or the next shareholders' meeting. Following this transaction, Hawkins directly holds 254,931 shares of MIMEDX common stock.
MiMedx Group (MDXG) AGM 2026 Summary
This article summarizes MiMedx Group (MDXG)'s 2026 Annual General Meeting (AGM) held virtually on June 10, 2026. Key items included the introduction of director nominees, an advisory vote on executive compensation, and the ratification of Deloitte & Touche LLP as the independent auditor. The article also provides a brief overview of recent financial events and proxy filings for MiMedx Group.
MDXG PE Ratio & Valuation, Is MDXG Overvalued
MiMedx Group Inc (MDXG) is currently considered undervalued based on its forward PS ratio of 1.78, which is significantly lower than its five-year average of 13.40. The fair price for MDXG is estimated to be between $3.75 and $6.93, suggesting it is undervalued by 1.93% compared to its current price of $3.68. Despite this, its P/S ratio of 1.78 is still 30.72% above the industry average for its competitors, which might be unsustainable given a revenue growth of -33.12%.
MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference
MIMEDX Group, Inc. (Nasdaq: MDXG) announced that its senior management will participate in the Craig-Hallum 23rd Annual Institutional Investor Conference on Thursday, May 28, 2026, in Minneapolis, MN. Investors interested in meeting with management should contact their Craig-Hallum representative. MIMEDX is a leader in healing solutions, providing products for wound care, burn, and surgical sectors.
Senior MiMedx execs heading to Craig-Hallum investor event
MiMedx Group, Inc. (Nasdaq: MDXG) announced that its senior management will attend the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28, 2026, in Minneapolis, MN. Interested institutional investors can request meetings with management through their Craig-Hallum representatives to discuss the company's strategies and recent performance. This participation follows a period of mixed signals for MiMedx, including product launches and cost-reduction efforts alongside a reduction in Q1 2026 sales guidance.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
Pomerantz LLP has announced an investigation into MiMedx Group, Inc. (NASDAQ: MDXG) following a significant drop in its stock price. The investigation concerns potential securities fraud or unlawful business practices after MiMedx reported disappointing Q1 2026 financial results, missing consensus estimates for both earnings per share and revenue. The company attributed the poor performance to new Medicare reimbursement policies affecting the advanced wound care space, leading to a decrease in its full-year net sales expectations.
MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference
MIMEDX will participate in the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28, 2026, in Minneapolis, MN. Senior management will be present, and interested investors can contact their Craig-Hallum representative for meetings. The company, a leader in healing solutions, focuses on wound care, burn, and surgical sectors with a vision to innovate and restore quality of life.
MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference
MIMEDX Group, Inc. announced that its senior management will participate in the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28, 2026, in Minneapolis, MN. Investors interested in meeting with management should contact their Craig-Hallum representative. MIMEDX is a leader in wound care, burn, and surgical healthcare products, aiming to be a global provider of healing solutions.
MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference
MiMedx Group, Inc. (Nasdaq: MDXG) announced that its senior management will attend the Craig-Hallum 23rd Annual Institutional Investor Conference on Thursday, May 28, 2026, in Minneapolis, MN. Investors are invited to contact their Craig-Hallum representative for meetings. MIMEDX specializes in healing solutions, particularly for chronic wounds, burns, and surgical applications.
MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference
MIMEDX Group, Inc. announced that its senior management will participate in the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28, 2026. The company is a leader in healing solutions, providing products for wound care, burn, and surgical applications. Investors interested in meeting with management can contact their Craig-Hallum representative.
MiMedx Group stock (US60251E1029): earnings turnaround and wound-care demand in focus
MiMedx Group has achieved profitability and raised its 2025 outlook, attracting investor attention to its regenerative wound-care business. The company focuses on placental tissue products for chronic wounds in US hospital and outpatient settings, navigating a competitive market with an evidence-driven differentiation strategy. Investors are watching its ability to sustain growth, manage regulatory demands, and adapt to healthcare policy changes.
MiMedx Group (MDXG) price target decreased by 18.75% to 6.63
This article reports that the price target for MiMedx Group (MDXG) has been decreased by 18.75%, bringing it down to $6.63. The specific reasons or analyst behind this adjustment are not detailed in this brief excerpt.
About Us | Oil & Gas Journal - MiMedx Group, Inc - Common Stock (Nasdaq:MDXG) Stock Quote
This article provides detailed stock information for MiMedx Group, Inc. (MDXG), including its current trading price, volume, historical performance, and recent news headlines. It also includes general information about Oil & Gas Journal, which hosts this stock quote data. The content highlights financial data, earnings reports, and market movements affecting MDXG.
MiMedx Group (MDXG) price target decreased by 18.75% to 6.63
This article reports that the price target for MiMedx Group (MDXG) has been decreased by 18.75%, bringing it down to $6.63. No additional details are provided in the current content.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
Pomerantz LLP is investigating potential securities fraud claims against MiMedx Group, Inc. (MDXG) following a significant drop in its stock price. The investigation comes after MiMedx reported disappointing Q1 2026 financial results, missing consensus estimates for both earnings and revenue, and subsequently lowered its full-year 2026 net sales expectations due to new Medicare reimbursement policies affecting the wound care market. Investors who suffered losses are encouraged to contact the law firm.
Is the Options Market Predicting a Spike in MiMedx Group Stock?
The options market suggests a potential spike in MiMedx Group (MDXG) stock, with high implied volatility seen in its June 2026 $10 Call options. While options traders are pricing in a significant move, the fundamental analysis places MiMedx Group as a Zacks Rank #3 (Hold) with a recent downgrade in earnings estimates. This creates a scenario where options traders might sell premium, betting against a large price movement.
MiMedx Group, Inc (NASDAQ:MDXG) Receives Consensus Recommendation of "Moderate Buy" from Analysts
MiMedx Group, Inc (NASDAQ:MDXG) has received a consensus "Moderate Buy" rating from seven covering firms, with an average 12-month price target of $8.50. Despite beating earnings expectations, the company's revenue fell short, and its stock was trading down 2.4% at $3.60. Institutional investors hold a significant 79.15% stake in the biopharmaceutical company.
MIMEDX Announces Launch of G4Derm® Plus
MIMEDX announced the commercial launch of G4Derm Plus, a new flowable biomimetic matrix that utilizes self-assembling peptide technology. This product, already available nationwide, expands MIMEDX's portfolio for surgical markets and is secured under Premier and Vizient GPO agreements. G4Derm Plus is designed for advanced wound management, promoting healthy tissue regrowth and acting as an antibacterial barrier.
MIMEDX Announces Launch of G4Derm® Plus
MIMEDX has launched G4Derm Plus, a new flowable biomimetic matrix that incorporates self-assembling peptide technology to aid in advanced wound management. The product, which is 510(k)-cleared, is already available to customers nationwide and is part of MIMEDX's strategy to expand its portfolio in surgical markets. G4Derm Plus is designed to support healthy tissue regrowth and act as an antibacterial barrier, and it is now accessible through Premier and Vizient GPO agreements.
MiMedx launches G4Derm Plus wound care product nationwide By Investing.com
MiMedx Group, Inc. has announced the nationwide commercial launch of G4Derm Plus, a novel wound management product utilizing self-assembling peptide technology. This launch aims to expand solutions for clinicians despite a recent 50% stock decline and first-quarter 2026 financial results that fell below expectations due to weak wound product sales and reimbursement changes.
MiMedx launches G4Derm Plus wound care product nationwide
MiMedx Group has commercially launched G4Derm Plus, a new wound management product, with initial sales already delivered across the U.S. This launch comes despite a recent 50% stock decline and the company missing Q1 2026 financial expectations, leading analysts to lower price targets. G4Derm Plus is a 510(k)-cleared flowable extracellular matrix leveraging self-assembling peptide technology for complex wound management.
MIMEDX Announces Launch of G4Derm® Plus
MIMEDX has commercially launched G4Derm Plus, an innovative flowable biomimetic matrix utilizing self-assembling peptide technology for advanced wound management. The product is 510(k)-cleared and is now available through major group purchasing organizations like Premier and Vizient. This launch expands MIMEDX's portfolio of solutions for surgical markets, aiming to provide clinicians with advanced regenerative therapies for complex wounds.
MIMEDX Announces Launch of G4Derm® Plus
MiMedx Group, Inc. (MIMEDX) has commercially launched G4Derm Plus, a flowable biomimetic matrix incorporating self-assembling peptide technology. This product, acquired by MIMEDX with exclusive U.S. distribution rights, is designed for advanced wound management and has already secured agreements with major group purchasing organizations like Premier and Vizient, facilitating national availability for clinicians. G4Derm Plus aims to support wound healing by encouraging tissue regrowth and providing an antibacterial barrier.
New wound-care matrix heads to hospitals via Premier, Vizient
MiMedx (Nasdaq: MDXG) has commercially launched G4Derm Plus, a 510(k)-cleared, acellular flowable extracellular matrix for advanced wound management. This new product, which uses self-assembling peptide technology, is now available nationwide through Premier and Vizient GPO agreements, expanding its reach into hospitals. The launch is part of MiMedx's strategy to broaden its surgical-focused product portfolio.
MiMedx Group (Nasdaq:MDXG) - Stock Analysis
This Simply Wall Street article provides a detailed stock analysis of MiMedx Group (MDXG), highlighting its current undervaluation by analysts despite projected earnings decline and recent revenue guidance cuts for 2026. The article covers past performance, recent news including Q1 2026 earnings misses and new product launches, insider transactions, and analyst price targets, indicating significant volatility and ongoing challenges in the wound care market and changes in Medicare reimbursement.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG
Pomerantz LLP is investigating potential claims on behalf of investors of MiMedx Group, Inc. (MDXG) following a significant drop in its stock price. The investigation comes after MiMedx missed consensus estimates for its first-quarter 2026 financial results, with non-GAAP EPS and revenue falling short of expectations. The company attributed the poor performance to confusion caused by new Medicare reimbursement policies in the advanced wound care space, leading to a downward revision of its full-year 2026 net sales forecast.
